Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Coverage (5)

• FDA staff flags concerns for Capricor’s Duchenne heart disease therapy WTVB · 2h ago
• Stock Traders Purchase Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) MarketBeat · 2h ago
• FDA staff flags data concerns about Capricor's therapy; shares plunge Reuters · 2h ago
• Is Capricor Therapeutics (CAPR) Trading At A Discount After Its Lease Deal And FDA Wait? Yahoo Finance · 2h ago
• Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug STAT · 2h ago

Related trends